Last updated: February 20, 2026
What is the Drug NDC 59148-0114?
NDC 59148-0114 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved by the FDA in May 2019 for the treatment of spinal muscular atrophy (SMA) in pediatric patients under two years old. It is a one-time intravenous infusion designed to replace the function of the defective or missing SMN1 gene.
Market Size and Demand Drivers
Patient Population
- SMA affects approximately 1 in 10,000 live births.
- Estimated U.S. incidence: 600–800 new cases annually.
- Target population: Patients under two years of age with SMA, aligning with FDA approval parameters.
Market Penetration
- As of 2022, approximately 3,000–4,000 U.S. patients are eligible, considering diagnosis rates and age restrictions.
- Key competitors include Spinraza (nusinersen) and Evrysdi (risdiplam), both approved for wider age groups but requiring multiple doses.
Sales Data (2022)
- Zolgensma: Generated approximately $1.25 billion in U.S. sales.
- Market share among SMA therapies: Zolgensma accounts for ~40% of the SMA treatment market, reflecting its novelty, pricing, and approval scope.
Price Overview and Cost Structure
List Price
- The list price for Zolgensma is $2.125 million per infusion.
- Price includes the one-time treatment, but actual expenses depend on healthcare setting and insurance negotiations.
Pricing Rationale
- The high upfront cost reflects the one-time nature and the potential for lifelong benefit, reducing ongoing treatment expenses.
- Pharma companies often negotiate discounts with payers; actual transaction prices are lower.
Cost Compared to Competitors
| Drug |
Dosing Regimen |
Approximate Price |
Notes |
| Zolgensma |
One-time infusion |
$2.125 million |
Approved for children under 2 years |
| Spinraza |
Multiple doses yearly |
$750,000 per year |
Cost accumulates over multiple years |
| Evrysdi |
Daily oral, ongoing |
Approx. $400,000 per year |
Ongoing treatment, less invasive |
External Factors Influencing Market and Price
Regulatory Policies
- Price controls and value-based pricing models are under consideration.
- CMS and private payers scrutinize high-cost therapies, influencing reimbursement.
Insurance Coverage
- Payers may seek outcomes-based agreements to mitigate financial risk.
- Access varies, with some reports indicating coverage denials or high patient cost-sharing.
Market Dynamics
- As more patients receive early diagnosis via newborn screening, demand is expected to increase.
- Expanded indications or approvals for wider age ranges could double the target population.
Price Projection Outlook (2023–2028)
Factors Affecting Pricing Trends
- Increasing competition from gene therapies or molecular treatments.
- Cost containment policies by payers.
- Potential for volume discounts and negotiation leverage.
Projected Price Trends
| Year |
Expected Price Range |
Key Considerations |
| 2023 |
$2.0–$2.125 million |
Settling after initial post-approval pricing stability |
| 2024 |
$1.9–$2.1 million |
Possible negotiations and discounts |
| 2025 |
$1.8–$2.0 million |
Competition may influence pricing adjustments |
| 2026 |
$1.7–$1.9 million |
Maturation of payer negotiations |
| 2027 |
$1.6–$1.8 million |
Broader adoption and increased market penetration |
Revenue Projections
- Assuming steady uptake, revenues from Zolgensma could reach $1.5–$2 billion annually by 2025.
- Market penetration could grow with increased newborn screening and expanded indications.
Summary
- Zolgensma's high upfront list price reflects its status as a potentially curative, one-time gene therapy for SMA in very young patients.
- Market growth depends heavily on diagnosis rates, payer acceptance, and competitive developments.
- Price reductions are possible, driven by market dynamics and policy shifts, but the therapy maintains a premium position in rare disease treatment.
Key Takeaways
- NDC 59148-0114 (Zolgensma) is a leading gene therapy with sales reaching approximately $1.25 billion in 2022.
- The list price stays at $2.125 million, but actual paid prices may vary due to discounts and negotiations.
- Market demand will grow with improved diagnosis and expanded approval windows.
- Payer pushback and policy shifts threaten margins but also encourage cost-effective utilization strategies.
- Long-term revenue growth depends on competition and regulatory changes.
FAQs
Q1: How does Zolgensma compare financially to traditional SMA treatments?
It has a significantly higher upfront cost but eliminates ongoing treatment expenses associated with drugs like Spinraza and Evrysdi.
Q2: Are there discounts or financial assistance programs for Zolgensma?
Yes, manufacturers often offer patient assistance programs and negotiate pricing with payers, which can significantly lower out-of-pocket costs.
Q3: What is the impact of expanded indications on Zolgensma’s market?
Expansion to older ages or broader SMA types could increase the patient base, potentially sustaining or raising prices.
Q4: How are payers approaching coverage for gene therapies like Zolgensma?
Many are implementing outcomes-based agreements and negotiating volume discounts to manage risk.
Q5: What potential threats could lower the price of Zolgensma?
Development of competing therapies, generics, or biosimilars, alongside regulatory policy changes, could pressure pricing downward.
References
[1] FDA. (2019). FDA approves Zolgensma for pediatric patients with SMA.
[2] Novartis. (2022). Zolgensma prescribing information.
[3] IQVIA. (2022). U.S. pharmaceutical sales data.
[4] CMS.gov. (2022). Policy updates on gene therapy reimbursement.
